

Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

GENENCOR INTERNATIONAL INC

Form 10-Q

May 15, 2002

-----  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
-----

FORM 10-Q

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2002

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM \_\_\_\_\_ TO \_\_\_\_\_

COMMISSION FILE NUMBER 000-31167

GENENCOR INTERNATIONAL, INC.  
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)  
-----

DELAWARE  
(STATE OR OTHER JURISDICTION OF  
INCORPORATION OR ORGANIZATION)

16-1362385  
(I.R.S. EMPLOYER  
IDENTIFICATION NUMBER)

925 PAGE MILL ROAD  
PALO ALTO, CALIFORNIA 94304  
(650) 846-7500

(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF  
REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES)

-----  
INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS  
REQUIRED TO BE FILED BY SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF  
1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE  
REGISTRANT WAS REQUIRED TO FILE SUCH REPORT(S), AND (2) HAS BEEN SUBJECT TO SUCH  
FILING REQUIREMENTS FOR THE PAST 90 DAYS

YES  NO

-----  
INDICATE THE NUMBER OF SHARES OUTSTANDING OF EACH OF THE ISSUER'S CLASSES OF  
COMMON STOCK, AS OF THE LATEST PRACTICABLE DATE.

CLASS	NUMBER OF SHARES OUTSTANDING AT APRIL 30, 2002
COMMON STOCK, PAR VALUE \$0.01 PER SHARE	59,672,706

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements:

Condensed Consolidated Unaudited Balance Sheets as of March 31, 2002 and December 31,  
Condensed Consolidated Unaudited Statements of Operations for the three months ended  
March 31, 2002 and 2001.....  
Condensed Consolidated Unaudited Statements of Cash Flows for the three months ended  
March 31, 2002 and 2001.....  
Notes to Condensed Consolidated Unaudited Financial Statements.....

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures About Market Risk.....

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.....  
Item 2. Changes in Securities and Use of Proceeds.....  
Item 3. Defaults Upon Senior Securities.....  
Item 4. Submission of Matters to a Vote of Security Holders.....  
Item 5. Other Information.....  
Item 6. Exhibits and Reports on Form 8-K.....

This Report contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These include statements concerning plans, objectives, goals, strategies, future events or performance and all other statements which are other than statements of historical fact, including without limitation, statements containing the words "believes," "anticipates," "expects," "estimates," "projects," "will," "may," "might" and words of a similar nature. The forward-looking statements contained in this Report reflect the Company's current beliefs and expectations on the date of this Report. Actual results, performance or outcomes may differ materially from those expressed in the forward-looking statements. Some of the important factors which, in the view of the Company, could cause actual results to differ from those expressed in the forward-looking statements are discussed in Item 2 of this Report and in the Company's 2001 Annual Report on Form 10-K. The Company disclaims any obligation to publicly announce any revisions to these forward-looking statements to reflect facts or circumstances of which the Company becomes aware after the date hereof.

Unless otherwise specified, all references in this Report to the "Company", "we", "us", "our", and "ourselves" refer to Genencor International, Inc. and its subsidiaries.

PART I. FINANCIAL INFORMATION

# Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

## ITEM 1. FINANCIAL STATEMENTS

### GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

	MARCH 31, 2002 ----
<b>ASSETS</b>	
Current assets:	
Cash and cash equivalents .....	\$ 145,103
Trade accounts receivable, net .....	47,222
Inventories .....	53,053
Other current assets .....	30,284
	-----
Total current assets .....	275,662
Property, plant and equipment, net .....	210,185
Goodwill .....	29,694
Intangible assets, net .....	37,032
Other assets .....	53,500
	-----
Total assets .....	\$ 606,073 =====
 <b>LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY</b>	
Current liabilities:	
Notes payable .....	\$ 8,367
Current maturities of long-term debt .....	28,290
Accounts payable and accrued expenses .....	44,890
Other current liabilities .....	11,851
	-----
Total current liabilities .....	93,398
Long-term debt .....	85,057
Other long-term liabilities .....	28,622
	-----
Total liabilities .....	207,077 -----
 Redeemable preferred stock:	
7 1/2% cumulative series A preferred stock, without par value, authorized 1 shares, 1 shares issued and outstanding .....	164,294
Stockholders' equity:	
Common stock, par value \$0.01 per share, 200,000 shares authorized, 59,947 and 59,941 shares issued at March 31, 2002 and December 31, 2001, respectively .....	600
Additional paid-in capital .....	346,720
Treasury stock, at cost, 350 shares .....	(5,630)
Deferred stock-based compensation .....	(2,863)
Notes receivable for common stock .....	(14,647)
Accumulated deficit .....	(16,344)
Accumulated other comprehensive loss .....	(73,134)
	-----

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

Total stockholders' equity .....	234,702 -----
Total liabilities, redeemable preferred stock and stockholders' equity	\$ 606,073 =====

The accompanying notes are an integral part of the condensed consolidated unaudited financial statements.

4

### GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

	THREE MONTHS ENDED	
	MARCH 31,	
	2002	2001
Revenues:		
Product revenue .....	\$ 75,548	\$ 75,268
Fees and royalty revenues .....	5,262	2,455
	80,810	77,723
Operating expenses:		
Cost of products sold .....	42,118	40,898
Research and development .....	15,632	12,924
Sales, marketing and business development.....	7,142	5,857
General and administrative .....	8,032	6,482
Amortization of intangible assets .....	1,307	2,397
Restructuring and related charges .....	16,294	--
Other (income)/expense .....	(1,347)	848
	89,178	69,406
Operating (loss)/income .....	(8,368)	8,317
Non operating expenses/(income):		
Interest expense .....	2,520	2,607
Interest income .....	(1,401)	(3,117)
	1,119	(510)
(Loss)/income before income taxes .....	(9,487)	8,827
(Benefit from)/provision for income taxes .....	(8,428)	2,550
Net (loss)/income .....	\$ (1,059)	\$ 6,277

Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

Net (loss applicable)/income available to holders of common stock .....	\$ (2,878)	\$ 4,458
	=====	=====
(Loss)/earnings per common share:		
Basic .....	\$ (0.05)	\$ 0.07
	=====	=====
Diluted .....	\$ (0.05)	\$ 0.07
	=====	=====
Weighted average common shares:		
Basic .....	59,596	59,908
	=====	=====
Diluted .....	60,057	61,459
	=====	=====

The accompanying notes are an integral part of the condensed consolidated unaudited financial statements.

5

GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS  
(AMOUNTS IN THOUSANDS)

	THREE MONTHS ENDED	
	MARCH 31,	
	2002	2001
	----	----
Cash flows from operating activities:		
Net (loss)/ income .....	\$ (1,059)	\$ 6,277
Adjustments to reconcile net (loss)/ income to net cash provided by operating activities:		
Depreciation and amortization .....	7,954	8,990
Amortization of deferred stock-based compensation .....	863	593
Non-cash portion of restructuring and related charges .....	9,225	--
Decrease (increase) in operating assets:		
Trade accounts receivable .....	1,071	436
Inventories .....	(2,048)	(4,313)
Other assets .....	(6,531)	4,252
Decrease in operating liabilities:		
Accounts payable and accrued expenses .....	(5,158)	(7,867)
Other liabilities .....	(3,309)	(3,701)
	-----	-----
Net cash provided by operating activities .	1,008	4,667
	-----	-----
Cash flows from investing activities:		
Purchases of property, plant and equipment .....	(2,346)	(4,706)
Purchases of intangible assets .....	(100)	--
Payment to acquire equity securities .....	(3,000)	--
Acquisition of business, net of cash acquired ....	(35,809)	--
	-----	-----
Net cash used in investing activities .....	(41,255)	(4,706)

Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

	-----	-----
Cash flows from financing activities:		
Proceeds from exercise of stock options .....	57	37
Proceeds from employee stock purchase plan .....	393	--
Net payments on revolving credit facility .....	(37)	--
Net payments on notes payable of foreign affiliate	(143)	(121)
Payment of long-term debt .....	(28,000)	--
	-----	-----
Net cash used in financing activities .....	(27,730)	(84)
	-----	-----
Effect of exchange rate changes on cash .....	(1,943)	(3,086)
	-----	-----
Net decrease in cash and cash equivalents .....	(69,920)	(3,209)
Cash and cash equivalents-- beginning of period ....	215,023	200,591
	-----	-----
Cash and cash equivalents-- end of period .....	\$ 145,103	\$ 197,382
	=====	=====

The accompanying notes are an integral part of the condensed consolidated unaudited financial statements.

GENENCOR INTERNATIONAL, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS  
(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

1 -- BASIS OF PRESENTATION

The condensed consolidated unaudited financial statements should be read in conjunction with the Company's audited consolidated financial statements and related footnotes for the year ended December 31, 2001, as included in the Company's Annual Report on Form 10-K. These interim financial statements have been prepared in conformity with the rules and regulations of the U.S. Securities and Exchange Commission. Certain disclosures normally included in financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations pertaining to interim financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for fair presentation of the interim financial statements have been included therein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year.

2 -- NEW ACCOUNTING PRONOUNCEMENTS

In June 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets." The Company adopted this statement as of January 1, 2002. This statement requires the recognition of separately identifiable intangible assets. Furthermore, it establishes amortization requirements based upon the ability of the intangible assets to provide cash flows. For those intangible assets with readily identifiable useful lives, amortization will be recorded in the statement of operations over such lives. Intangible assets, such as goodwill,

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

which have indefinite lives, will not result in periodic amortization, but must be tested at least annually for impairment.

With the adoption of SFAS 142, the Company reassessed the useful lives and residual values of all acquired intangible assets to make any necessary amortization period adjustments. Based on that assessment, goodwill and certain previously acquired technology were determined to have indefinite useful lives. There were no adjustments made to the amortization periods or residual values of other intangible assets. As a result, certain reclassifications were made to previously issued financial statements to conform to the presentation required by SFAS 142. The Company completed the first step of the transitional goodwill and indefinite-lived intangible impairment tests and has determined that no potential impairment exists. As a result, the Company has recognized no transitional impairment loss to date in fiscal 2002 in connection with the adoption of SFAS No. 142.

In August 2001, the Financial Accounting Standards Board issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." SFAS No. 144 supercedes SFAS No. 121 "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of." SFAS No. 144 addresses the accounting for long-lived assets to be disposed of by sale and resulting implementation issues. This statement requires the measurement of long-lived assets at the lower of carrying amount or fair value less cost to sell, whether reported in continuing operations or in discontinued operations. This statement is effective for financial statements issued for fiscal years beginning after December 15, 2001. The Company adopted SFAS No. 144 as of January 1, 2002. There was no financial impact as a result of the adoption. The Company will apply its provisions to future impairments or disposals of long-lived assets as they occur.

### 3 -- EARNINGS PER SHARE

SFAS No. 128, "Earnings per Share," requires the disclosure of basic and diluted earnings per share. Basic earnings per share is computed based on the weighted average number of common shares outstanding during the period. In arriving at net (loss applicable)/ income available to holders of common stock, undeclared and unpaid dividends on redeemable preferred stock of \$1,819 were deducted from net (loss)/income for each quarter presented.

Diluted (loss)/earnings per common share reflects the potential dilution that could occur if dilutive securities and other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in

7

the net (loss applicable)/income available to holders of common stock of the Company. As a result of stock options outstanding under the Company's Stock Option and Stock Appreciation Right Plan, there were dilutive securities for the three months ended March 31, 2002 and 2001. The weighted-average impact of these has been reflected in the calculation of diluted (loss)/earnings per common share for the respective periods presented.

The following table reflects the calculation of basic and diluted (loss)/earnings per common share for the three months ended March 31:

2002	2001
----	----

Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

Net (loss)/income .....	\$ (1,059)	\$ 6,277
Less: Accrued dividends on preferred stock .....	(1,819)	(1,819)
	-----	-----
Net (loss applicable)/income available to holders of common stock .....	\$ (2,878)	\$ 4,458
	=====	=====
Weighted average common shares:		
Basic .....	59,596	59,908
Effect of stock options .....	461	1,551
	-----	-----
Diluted .....	60,057	61,459
	=====	=====
(Loss)/earnings per common share:		
Basic .....	\$ (0.05)	\$ 0.07
	=====	=====
Diluted .....	\$ (0.05)	\$ 0.07
	=====	=====

4 -- FEES AND ROYALTY REVENUES

During October 2001, the Company entered into a strategic alliance with Dow Corning Corporation to create a new, proprietary technology platform for the development of new biomaterials. During the first quarter of 2002, the Company recorded \$2,638 in research funding revenues from this collaboration.

5 -- INVENTORIES

Inventories consist of the following:

	MARCH 31, 2002	DECEMBER 31, 2001
	----	----
Raw materials .....	\$ 7,911	\$ 7,526
Work-in-progress .....	8,641	7,454
Finished goods .....	36,501	33,402
	-----	-----
Inventories .....	\$53,053	\$48,382
	=====	=====

6 --GOODWILL AND OTHER INTANGIBLE ASSETS

As discussed in Note 2 above, the Company adopted the provisions of SFAS No. 142 effective as of January 1, 2002. Accordingly, the Company no longer amortizes goodwill or other intangible assets with indefinite useful lives. The Company has identified such other indefinite-lived intangible assets to include certain previously acquired technology. The Company will periodically evaluate its indefinite-lived intangible assets for impairment in accordance with the provisions of SFAS No. 142. The Company also has other intangible assets, such as patents, licenses, and customer lists, which will continue to be amortized over a weighted average useful life of 13 years using the straight-line method. These assets are expected to have no residual value once they are fully amortized.



Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

8

The following table summarizes the changes in each major class of intangible assets from January 1, 2002 through March 31, 2002:

	INTANGIBLE ASSETS		
	TECHNOLOGY	OTHER AMORTIZABLE ASSETS	TOTAL
Balances, January 1, 2002.....	\$ 15,617	\$ 51,890	\$ 67,507
Acquired intangible assets...	-	-	-
Foreign currency translation.	-	-	-
Balances, March 31, 2002.....	\$ 15,617	51,890	67,507
Less: Accumulated amortization.....		30,475	30,475
Intangible assets, net.....		\$ 21,415	\$ 37,032

In conjunction with the acquisition discussed in Note 10, the Company acquired certain intangible assets during the three months ended March 31, 2002. The Company is currently in the process of segregating these intangible assets among the major classes. As such, the estimated value of these intangible assets has been included in goodwill as of March 31, 2002 and will be reclassified among the major classes once the Company completes its allocation of the purchase price.

The following table reflects the comparative net (loss)/income and (loss)/earnings per common share as though the provisions of SFAS No. 142 were in effect for the three months ended March 31, 2001 and three months ended March 31, 2002:

	FOR THE THREE MONTHS ENDED MARCH 31,	
	2002	2001
Net (loss)/income as reported .....	\$ (2,878)	\$ 4,458
Add back amortization:		
Goodwill (\$0 and \$288 pre-tax) .....	--	179
Technology (\$0 and \$838 pre-tax) .....	--	519
Net (loss)/income as adjusted .....	\$ (2,878)	\$ 5,156

Basic (loss)/earnings per share:

Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

As reported .....	\$ (0.05)	\$ 0.07
Amortization .....	--	0.01
	-----	-----
As adjusted .....	\$ (0.05)	\$ 0.08
	=====	=====
Diluted (loss)/earnings per share:		
As reported .....	\$ (0.05)	\$ 0.07
Amortization .....	--	0.01
	-----	-----
As adjusted .....	\$ (0.05)	\$ 0.08
	=====	=====

Estimated fiscal year amortization expense is as follows:

2002.....	\$5,200
2003.....	5,200
2004.....	4,500
2005.....	4,500
2006.....	4,500

9

7 --STOCKHOLDERS' EQUITY

Accumulated other comprehensive loss consists of the following:

	FOREIGN CURRENCY TRANSLATION ADJUSTMENT	MARKETABLE SECURITIES VALUATION ADJUSTMENT	ACCUMULATED OTHER COMPREHENSIVE LOSS
	-----	-----	-----
Balances, December 31, 2001 ....	\$ (62,599)	\$ (639)	\$ (63,238)
Current period change .....	(9,565)	(331)	(9,896)
	-----	-----	-----
Balances, March 31, 2002 .....	\$ (72,164)	\$ (970)	\$ (73,134)
	=====	=====	=====

The change in the marketable securities valuation adjustment for the three months ended March 31, 2002, of \$331, (\$522 pre-tax) relates to unrealized holding losses on the Company's available-for-sale securities.

8 -- INCOME TAXES

The effective income tax rate for the three months ended March 31, 2002 was an 89% tax benefit, compared to a 29% tax expense for the three months ended March 31, 2001. The effective rate for the three months ended March 31, 2002 was driven by anticipated annual tax benefits from operating losses in high tax jurisdictions, partially offset by taxes on operating income generated in low tax jurisdictions. Factors that affect the Company's estimated annual effective income tax rate include increased research and development expenditures in the

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

United States, the statutory income tax rates in foreign jurisdictions, amortization of certain intangible assets and other items which are not deductible for tax purposes, and research and experimentation tax credits. The rate also included the effect of the one-time restructuring and related charges. The entire tax benefit related to these restructuring and related charges of approximately \$6,000 was recorded in the first quarter of 2002. During the three months ended March 31, 2002 and 2001 the Company was subject to a tax ruling in the Netherlands that reduces the local effective income tax rate from 35.0% to 17.5%. This ruling will expire in 2005.

### 9 -- COLLABORATIVE AGREEMENTS

During January 2002, the Company entered into a two-year extendable collaboration agreement with The Johns Hopkins University for the research of therapeutic vaccines and other immunotherapies targeting cancers and oncogenic viruses. Under the agreement, the Company received worldwide licenses to certain proprietary technologies as well as exclusive commercialization rights to any products developed through the agreement. This collaboration required the Company to pay an up front license fee as well as annual royalties. The agreement also requires certain research and development funding and has potential for additional milestone payments and royalties on future product sales.

Also during January 2002, the Company formed a strategic alliance with Seattle Genetics, Inc., to jointly discover and develop a class of cancer therapeutics. Under terms of the alliance, the companies will share preclinical and clinical development costs and have the right to jointly commercialize any resulting products. The Company has made an equity investment in Seattle Genetics of \$3,000 and agreed to pay certain fees and milestone payments. Seattle Genetics has also agreed to make certain milestone payments to the Company.

10

### 10 -- ACQUISITION

During February 2002, the Company acquired Enzyme Bio-Systems Ltd. (EBS) from Corn Products International, Inc. for a total cash purchase price of \$35,809 and the assumption of \$974 in debt. As part of this transaction, the Company entered into a seven-year supply agreement for a majority of Corn Products International, Inc.'s North American enzyme requirements. The acquisition has been accounted for under the purchase method in accordance with SFAS No. 141, "Business Combinations." The acquired entity's results of operations have been consolidated with the Company's results of operations since the acquisition date. The Company is continuing to evaluate the allocation of the purchase price for the acquisition, including the segregation of separately identifiable intangible assets. The Company anticipates that this process will be completed during the quarter ended June 30, 2002. According to the Company's preliminary allocation of the purchase price, the net assets acquired consist of the following as of February 2002:

Working capital.....	\$	4,100
Property, plant and equipment.....		22,000
Intangible assets.....		10,400
Long-term liabilities.....		(691)
		-----
	\$	35,809
		=====

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

Included in working capital acquired is a provision to restructure the entity of approximately \$1,000, which primarily consists of the employee-related costs to eliminate approximately 22 positions. All affected employees were notified immediately of the restructuring plan. As of March 31, 2002, costs totaling \$985 had been charged to this restructuring provision.

### 11 -- RESTRUCTURING AND RELATED CHARGES

During February 2002, as a result of the acquisition of EBS and general economic conditions in Latin America, including the devaluation of the Argentine peso, the Company engaged in a plan to restructure its overall supply infrastructure by ceasing operations at its Elkhart, Indiana plant and downsizing its Argentine facilities. Approximately 122 positions will be eliminated as a result of this restructuring. All affected employees were notified immediately of the restructuring plan. As of March 31, 2002, 62 employees had terminated their employment with the Company.

As a result of the plan, restructuring and related charges of \$16,294 were recorded in the Company's operating earnings in the three months ended March 31, 2002. These charges were primarily driven by employee severance and related costs of approximately \$3,762, costs to dismantle portions of the restructured facilities of \$1,000, costs to terminate long-term utility agreements of \$300, other costs totaling \$400, and \$9,225 for property, plant and equipment that was deemed impaired as it would no longer be utilized by the Company after the restructuring. The impairment charge was determined based on remaining book value, as the Company believes there is no active market in which to sell the specific assets. The Company expects full implementation to be completed in the fourth quarter of 2002. In addition, the Company recorded costs related to the restructuring, such as those related to the transition of activities between Elkhart and EBS, of \$1,607 as incurred during the three months ended March 31, 2002. At March 31, 2002, the Company had a remaining liability of \$5,183 related to this restructuring.

11

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and the notes to those statements included in our 2001 Annual Report on Form 10-K, and the condensed consolidated unaudited financial statements and related notes included elsewhere in this report.

### OVERVIEW

We are a diversified biotechnology company that develops and delivers products and/or services to the industrial, consumer, agri-processing and health care markets. Our current revenues result primarily from the sale of enzyme products to the cleaning, grain processing and textile industries, with the remainder from research funding and royalties. We intend to apply our proven and proprietary technologies and manufacturing capabilities to expand sales in our existing markets and address new opportunities in the health care, agri-processing, industrial and consumer markets. We have formed, and plan to

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

continue to form, strategic alliances with market leaders to collaborate with us to develop and launch products.

We manufacture our products through our nine manufacturing facilities located in the United States, Finland, Belgium, China and Argentina. We conduct our sales and marketing activities through our direct sales organizations in the United States, the Netherlands, Singapore, Japan and Argentina. For the year ended December 31, 2001, we derived approximately 50% of our revenues from our foreign operations. For the three months ended March 31, 2002, we derived approximately 50% of our revenues from our foreign operations.

### NEW ACCOUNTING PRONOUNCEMENTS

In June 2001, the Financial Accounting Standards Board issued SFAS No. 142, "Goodwill and Other Intangible Assets." We adopted this statement as of January 1, 2002. This statement requires the recognition of separately identifiable intangible assets. Furthermore, it establishes amortization requirements based upon the ability of the intangible assets to provide cash flows. For those intangible assets with readily identifiable useful lives, amortization will be recorded in the statement of operations over such lives. Intangible assets, such as goodwill, which have indefinite lives, will not result in periodic amortization, but must be tested at least annually for impairment. This statement may result in reclassifications in our financial statements of pre-existing intangible assets.

With the adoption of SFAS 142, we reassessed the useful lives and residual values of all acquired intangible assets to make any necessary amortization period adjustments. Based on that assessment, goodwill and certain previously acquired technology were determined to have indefinite useful lives. Also, there were no adjustments made to the amortization periods or residual values of other intangible assets. As a result, certain reclassifications were made to previously issued financial statements to conform to the presentation required by SFAS 142. We completed the first step of the transitional goodwill and indefinite-lived intangible impairment tests and have determined that no potential impairment exists. As a result, we recognized no transitional impairment loss to date in fiscal 2002 in connection with the adoption of SFAS No. 142.

In August 2001, the Financial Accounting Standards Board issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." SFAS No. 144 supercedes SFAS No. 121 "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of." SFAS No. 144 addresses the accounting for long-lived assets to be disposed of by sale and resulting implementation issues. This statement requires the measurement of long-lived assets at the lower of carrying amount or fair value less cost to sell, whether reported in continuing operations or in discontinued operations. This statement is effective for financial statements issued for fiscal years beginning after December 15, 2001. We adopted SFAS No. 144 as of January 1, 2002. There was no financial impact as a result of the adoption. We will apply its provisions to future impairments or disposals of long-lived assets as they occur.

### SUMMARY OF RESULTS

For the three months ended March 31, 2002, we reported a net loss applicable to common stockholders of \$2.9 million, or a loss of \$0.05 per diluted share, compared to net income available to common stockholders of \$4.5 million, or \$0.07 per diluted share for the

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

three months ended March 31, 2001. During the three months ended March 31, 2002, we recorded restructuring and related charges of \$16.3 million. Before these charges, we would have reported net income available to common stockholders of \$7.4 million, or \$0.12 per diluted share.

### RECENT DEVELOPMENTS

During January 2002, we entered into a two-year extendable collaboration agreement with The Johns Hopkins University for the research of therapeutic vaccines and other immunotherapies targeting cancers and oncogenic viruses. Under the agreement, we received worldwide licenses to certain proprietary technologies as well as exclusive commercialization rights to any products developed through the agreement. This collaboration required us to pay an up front license fee as well as annual royalties. The agreement also requires certain research and development funding and has potential for additional milestone payments and royalties on future product sales.

Also during January 2002, we formed a strategic alliance with Seattle Genetics, Inc., to jointly discover and develop a class of cancer therapeutics. Under terms of the alliance, the companies will share preclinical and clinical development costs and have the right to jointly commercialize any resulting products. We made an equity investment in Seattle Genetics of \$3.0 million and agreed to pay certain fees and milestone payments. Seattle Genetics has also agreed to make certain milestone payments to us.

### RESULTS OF OPERATIONS

Comparison of the Three Months Ended March 31, 2002 and 2001

**Revenues.** Total revenues for the three-month period ended March 31, 2002 increased \$3.1 million, or 4%, to \$80.8 million from the three-month period ended March 31, 2001, primarily due to an increase in fees and royalty revenues.

**Product Revenues.** Product revenues for the three months ended March 31, 2002 increased \$0.2 million to \$75.5 million from the three months ended March 31, 2001. Excluding the impact of the stronger U.S. dollar against foreign currencies, primarily the Euro, product revenues for the three months ended March 31, 2002 would have increased by approximately 4%, to \$78.0 million. For the three months ended March 31, 2002, unit volume/mix grew 7%, while average prices fell 3%. Volume increased primarily due to increased protease enzyme sales to a major customer and increased sales volume with our grain processing customers.

Regionally, North American product revenues for the three months ended March 31, 2002 increased \$0.2 million, or 1%, to \$36.2 million from the three months ended March 31, 2001, driven primarily by sales to our grain processing customers, partially offset by decreased sales to cleaning and fabric care customers. Product revenues in Europe, Africa and the Middle East for the three months ended March 31, 2002 increased \$1.3 million, or 5%, to \$27.8 million from the three months ended March 31, 2001, driven primarily by increased sales to cleaning and fabric care customers. Our product revenues in Latin America for the three months ended March 31, 2002 declined \$1.7 million, or 40%, to \$2.6 million from the three months ended March 31, 2001, primarily due to decreased sales to our cleaning and fabric care customers and grain processing customers. Product revenues in the Asia Pacific region increased \$0.5 million, or 6%, to \$8.9 million for three months ended March 31, 2002 from the three months ended March 31, 2001 due mainly to increased sales to our grain processing customers.

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

Fees and Royalty Revenues. Fees and royalty revenues increased \$2.8 million to \$5.3 million for the three months ended March 31, 2002 from the three months ended March 31, 2001, due primarily to an increase in customer funded research.

Funded research revenues for the three months ended March 31, 2002 increased \$2.6 million, to \$4.8 million from the three months ended March 31, 2001. Revenues generated by research funding result from collaborative agreements with various parties, including the U.S. Government, whereby we perform research activities and receive revenues that partially reimburse us for expenses incurred. Under such agreements, we retain a proprietary interest in the products and technology developed. Our funded research revenue as it relates to U.S. Government collaborations increased \$0.1 million, or 13%, to \$0.9 million for the three months ended March 31, 2002 from the three months ended March 31, 2001 primarily due to funding provided by the National Renewable Energy Laboratory to develop an enzymatic process to convert biomass into bioethanol. Funded research revenues provided by customers increased \$2.5 million, to \$3.9 million for the three months ended March 31, 2002 from the three months ended March 31, 2001, primarily driven by funding from a strategic alliance we entered into with the Dow Corning Corporation during the fourth quarter of 2001.

13

Royalties increased \$0.1 million, or 33%, to \$0.4 million for the three months ended March 31, 2002 from the three months ended March 31, 2001, due primarily to an additional customer that pays royalties to us based on the sales of its products that are produced using our technology.

### Operating Expenses

Cost of Products Sold. Cost of products sold increased \$1.2 million, or 3%, to \$42.1 million for the three months ended March 31, 2002 from the three months ended March 31, 2001. Our expanded sales volume/mix increased costs \$2.3 million along with the sale of higher cost inventories of \$1.6 million, partially offset by reductions due to the impact of the stronger U.S. dollar against foreign currencies of \$2.7 million.

Gross Profit and Margins from Products Sold. Gross profit from products sold decreased \$1.0 million, or 3%, to \$33.4 million for the three months ended March 31, 2002 from the three months ended March 31, 2001. This overall decrease was caused by significant product revenue related factors including a 7% increase in volume/mix processed through our plants, partially offset by an average price decline of 3%. This net decrease in gross profit was also affected by a \$0.2 million decrease due to the impact of the stronger U.S. dollar against foreign currencies. As a result of these factors, gross margin on product revenue decreased to 44.2% for the three months ended March 31, 2002 from 45.7% for the three months ended March 31, 2001.

Research and Development. Research and development expenses primarily consist of the personnel related, consulting, and facilities costs incurred in connection with our research activities conducted in Palo Alto, California, and Leiden, the Netherlands. These expenses increased \$2.7 million, or 21%, to \$15.6 million for the three months ended March 31, 2002 from the three months ended March 31, 2001, as we increased our investment in technology and product development for new markets and hired additional internal staff to support our health care and other initiatives. As a part of total research and development expenses, estimated expenses related to research collaborations partially funded by customers increased \$1.9 million to \$3.8 million for the three months ended March 31, 2002 from the three months ended March 31, 2001.

Sales, Marketing and Business Development. Sales, marketing and business development expenses primarily consist of the personnel related and marketing

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

costs incurred by our global sales force. These expenses increased \$1.2 million, or 20%, to \$7.1 million for the three months ended March 31, 2002 from the three months ended March 31, 2001, due primarily to increased personnel related costs, including salaries, benefits, commissions and travel expenses of \$0.5 million, incentive compensation of \$0.6 million and employee programs of \$0.4 million, partially offset by decreases in outside services of \$0.2 million.

**General and Administrative.** General and administrative expenses include the costs of our corporate executive, finance, information technology, legal, human resources, and communications functions. In total, these expenses increased \$1.5 million, or 23%, to \$8.0 million for the three months ended March 31, 2002 from the three months ended March 31, 2001, due primarily to increased outside services of \$1.1 million, personnel related costs, including salaries, benefits and travel expenses of \$0.2 million and advertising and promotions costs of approximately \$0.1 million.

**Amortization of Intangible Assets.** We amortize our intangible assets, consisting of patents, licenses and other contractual agreements, on a straight-line basis over their estimated useful lives. Amortization expense decreased \$1.1 million, or 46%, to \$1.3 million for the three months ended March 31, 2002 from the three months ended March 31, 2001 due primarily to the implementation of SFAS No. 142, "Goodwill and Other Intangible Assets."

**Other Expense and Income.** Other expense and income relates primarily to foreign currency exchange gains and losses on transactions denominated in other than the functional currency of the entity in which the transaction occurred. Other income for the three months ended March 31, 2002 was \$1.3 million, as compared with other expense of \$0.8 million for the three months ended March 31, 2001. This \$2.1 million increase in income was due mainly to an increase in Argentine peso-driven foreign currency transaction gains during the three months ended March 31, 2002.

**Deferred Compensation.** We measure deferred compensation for options granted to employees as the difference between the grant price and the estimated fair value of our common stock on the date we granted the options. In connection with the grant of stock options to employees during 2000, amortization of deferred compensation expense for the three months ended March 31, 2002 was \$0.9 million and for the three months ended March 31, 2001 was \$0.6 million.

14

During the fourth quarter of 2001, we converted previously issued stock appreciation rights (SARs) to stock options. As a result, the SARs were canceled and new stock options were granted at the exercise price and with vesting beginning as of the grant date of the previously issued SARs. For the new stock options, stock-based compensation was then calculated as the difference between the exercise price and the estimated fair value of the new stock options on the conversion date.

In total, amortization of deferred stock-based compensation expense was \$0.9 million and \$0.6 million for the three months ended March 31, 2002 and 2001, respectively, and was reported in our Consolidated Statement of Operations as follows (in millions):

	2002	2001
	----	----
Cost of products sold .....	\$0.1	\$0.0



## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

Research and development .....	0.2	0.2
Sales, marketing and business development .....	0.4	0.2
General and administrative .....	0.2	0.2
	----	----
Total amortization of deferred compensation expense ....	\$0.9	\$0.6
	====	====

### Non Operating Expense and Income

Interest Income. Interest income decreased \$1.7 million, or 55%, to \$1.4 million for the three months ended March 31, 2002 from the three months ended March 31, 2001 due mainly to the reduction of our cash balances, discussed below under the heading "Liquidity and Capital Resources."

Income Taxes. The effective income tax rate for the three months ended March 31, 2002 was an 89% tax benefit, compared to a 29% tax expense for the three months ended March 31, 2001. The effective rate for the three months ended March 31, 2002 was driven by anticipated annual tax benefits from operating losses in high tax jurisdictions, partially offset by taxes on operating income generated in low tax jurisdictions. Factors that affect our estimated annual effective income tax rate include increased research and development expenditures in the United States, the statutory income tax rates in foreign jurisdictions, amortization of certain intangible assets and other items which are not deductible for tax purposes, and research and experimentation tax credits. The rate also included the effect of the one-time restructuring and related charges. The entire tax benefit related to these restructuring and related charges of approximately \$6.0 million was recorded in the first quarter of 2002. During both periods we were subject to a tax ruling in the Netherlands that reduces the local effective income tax rate from 35.0% to 17.5%. This ruling will expire in 2005.

### ACQUISITION

During February 2002, we acquired Enzyme Bio-Systems Ltd. (EBS) from Corn Products International, Inc. for a total cash purchase price of \$35.8 million and the assumption of \$1.0 million in debt. As part of this transaction, we entered into a seven-year supply agreement for a majority of Corn Products International, Inc.'s North American enzyme requirements. The acquisition has been accounted for under the purchase method in accordance with SFAS No. 141, "Business Combinations." The acquired entity's results of operations have been consolidated with our results of operations since the acquisition date. We are continuing to evaluate the allocation of the purchase price for the acquisition, including the segregation of separately identifiable intangible assets. We anticipate that this process will be completed during the quarter ended June 30, 2002. According to our preliminary allocation of the purchase price, the net assets acquired consist of the following as of February 2002 (in millions):

Working capital .....		\$ 4.1
Property, plant and equipment .....		22.0
Intangible assets .....		10.4
Long-term liabilities .....		(0.7)
		----
		\$35.8
		====

Included in working capital acquired is a provision to restructure the

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

entity of approximately \$1.0 million, which primarily consists of the employee-related costs to eliminate approximately 22 positions. All affected employees were notified immediately of the restructuring plan. As of March 31, 2002, costs totaling \$1.0 million had been charged to this restructuring provision.

15

### RESTRUCTURING AND RELATED CHARGES

During February 2002, as a result of the acquisition of EBS and general economic conditions in Latin America, including the devaluation of the Argentine peso, we engaged in a plan to restructure our overall supply infrastructure by ceasing operations at our Elkhart, Indiana plant and downsizing our Argentine facilities. Approximately 122 positions will be eliminated as a result of this restructuring. All affected employees were notified immediately of the restructuring plan. As of March 31, 2002, 62 employees had terminated their employment with us.

As a result of the plan, restructuring and related charges of \$16.3 million were recorded in our operating earnings in the three months ended March 31, 2002. These charges were primarily driven by employee severance and related costs of approximately \$3.8 million, costs to dismantle portions of the restructured facilities of \$1.0 million, costs to terminate long-term utility agreements of \$0.3 million, other costs totaling \$0.4 million, and \$9.2 million for property, plant and equipment that was deemed impaired as it would no longer be utilized by us after the restructuring. The impairment charge was determined based on remaining book value, as we believe there is no active market in which to sell the specific assets. We expect full implementation to be completed in the fourth quarter of 2002. In addition, we recorded costs related to the restructuring, such as those related to the transition of activities between Elkhart and EBS, of \$1.6 million as incurred during the three months ended March 31, 2002. At March 31, 2002, we had a remaining liability of \$5.2 million related to this restructuring.

### LIQUIDITY AND CAPITAL RESOURCES

Our funding needs consist primarily of capital expenditures, research and development activities, sales and marketing expenses, and general corporate purposes. We have financed our operations primarily through cash from the sale of products, the sale of common stock, research and development funding from partners, government grants, and short-term and long-term borrowings.

We believe that our current cash and cash equivalent balances plus funds to be provided from our current year operating activities together with those available under our lines of credit will satisfy our funding needs over the next twelve months. Factors that could negatively impact our cash position include, but are not limited to, future levels of product, fees and royalty revenues, expense levels, capital expenditures, acquisitions, and foreign currency exchange rate fluctuations.

As of March 31, 2002, cash and cash equivalents totaled \$145.1 million. The funds were invested in short-term instruments, including A1-P1 rated commercial paper, master notes, U.S. treasury bills, institutional money market funds, auction rate preferred securities and bank deposits.

Cash provided by operations was \$1.0 million and \$4.7 million for the three months ended March 31, 2002 and 2001, respectively. The decrease of \$3.7 million in 2002 from 2001 was generated principally by operating losses, net of non-cash items such as depreciation and amortization, and changes in operating assets and

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

liabilities.

Cash used by investing activities was \$41.3 million and \$4.7 million for the three months ended March 31, 2002 and 2001, respectively. This increase of \$36.6 million was driven primarily by the EBS acquisition of \$35.8 million and the equity investment in Seattle Genetics, Inc. of \$3.0 million during the three months ended March 31, 2002. Capital expenditures for the first quarter were \$2.3 million in 2002 compared with \$4.7 million in 2001. A significant portion of the capital spending included process improvement projects at our manufacturing and research and development facilities and information technology enhancements.

Cash used by financing activities was \$27.7 million and \$0.1 million for the three months ended March 31, 2002 and 2001, respectively. This difference of \$27.6 million was primarily driven by the 2002 payment made on our long-term debt of \$28.0 million. No dividends were paid to common stockholders during the three months ended March 31, 2002 and 2001. We currently intend to retain future earnings to finance the expansion of our business. Any future determination to pay cash dividends to our common stockholders will be at the discretion of our board of directors and will depend upon our financial condition, results of operations, capital requirements, general business conditions and other factors that the board of directors may deem relevant, including covenants in our debt instruments that may limit our ability to declare and pay cash dividends on our capital stock. Covenants in our senior note agreement restrict the payment of dividends or other distributions in cash or other property to the extent the payment puts us in default of these covenants. Such covenants include, but are not limited to, maintaining a debt to total capitalization of no greater than 55% and a maximum ratio of debt to earnings before interest, taxes, depreciation and amortization (EBITDA) of 3.5:1.

16

As of March 31, 2002, we had a \$60.0 million revolving credit facility with a syndicate of banks, which is available for general corporate purposes. The facility, which consists of two separate credit agreements, makes available to us \$40.0 million of committed borrowings pursuant to a credit agreement that expires on January 31, 2004, and \$20.0 million of committed borrowings pursuant to a 364-day credit agreement that expires on January 30, 2003. The combined facility carries facility fees of 0.35% on the amount of unborrowed principal under the \$40.0 million agreement and 0.30% under the \$20.0 million agreement. As of April 30, 2002, there were no borrowings under either facility.

Our long-term debt consists primarily of the 6.82% senior notes issued in 1996 to certain institutional investors. The remaining principal amount of these notes is \$112.0 million. Annual installment payments of \$28.0 million commenced on March 30, 2002. We are currently in compliance with all of the financial covenants included in the senior note agreement.

### MARKET RISK

Foreign currency risk and interest rate risk are the primary sources of our market risk. Foreign operations, mainly denominated in Euros, accounted for approximately 50% of our revenues for the three months ended March 31, 2002 and 2001. We believe that we mitigate this risk by locating our manufacturing facilities so that the costs are denominated in the same currency as our product revenues. We may manage the foreign currency exposures that remain through the use of foreign currency forward contracts, currency options and off-setting currency positions in assets and liabilities where deemed appropriate. At March 31, 2002, there were no forward contracts or option contracts outstanding. There were no material foreign currency gains in connection with these types of

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

contracts recorded in the statement of operations for the three months ended March 31, 2002.

As of March 31, 2002, cash and cash equivalents totaled \$145.1 million. Of this amount, \$58.7 million was denominated in Euros. The remainder, or \$86.4 million, was primarily denominated in U.S. dollars. Other than the first installment of \$28.0 million paid in March 30, 2002 under our 6.82% senior notes discussed under the heading "Liquidity and Capital Resources" in this Report, short-term debt outstanding at March 31, 2002 was not significant. To the extent U.S. dollar and Euro interest rates fluctuate either up or down, the return on the cash investments will also fluctuate. To the extent such Euro cash investments remain outstanding, we will be subject to the risks of future foreign exchange fluctuations and the impact on the translation of these cash investments into U.S. dollars.

### Interest Rates

Our interest income is sensitive to changes in the general level of short-term interest rates primarily in the United States and Europe. In this regard, changes in the U.S. dollar and Euro currency rates affect the interest earned on our cash equivalents, short-term investments, and long-term investments. Our interest expense is generated primarily from fixed rate debt, the \$112.0 million 6.82% senior notes outstanding at March 31, 2002, which mature evenly in installments of \$28.0 million per year commencing March 30, 2003.

On January 31, 2002, we entered into an interest rate swap contract to pay a variable rate of interest based on the six month London Interbank Offered Rate (LIBOR) and receive fixed rates of interest at 6.82% on a \$28.0 million notional amount of our long-term indebtedness. The contract will mature on March 30, 2004. The net gain or loss on the ineffective portion of the interest rate swap contract was not material as of March 31, 2002. On May 14, 2002 we entered into an interest rate swap contract to pay a variable rate of interest based on the six month London Interbank Offered Rate (LIBOR) and receive fixed rates of interest at 6.82% on an additional \$28.0 million notional amount of our long-term indebtedness. The contract will mature on March 30, 2004. These contracts together, effectively converted 50% of our fixed rate debt to floating rate debt. Both financial instruments are entered with major, creditworthy banks and thus are not considered to be subject to significant counter-party credit risk.

### Foreign Currency Exposure

We conduct business throughout the world. During the three month period ended March 31, 2002, we derived approximately 50% of our revenues from foreign operations, and these foreign operations generated income that offset our net losses during the same three-month period. Economic conditions in countries where we conduct business and changing foreign currency exchange

17

rates affect our financial position and results of operations. We are exposed to changes in exchange rates in Europe, Latin America, and Asia. The Euro and the Argentine peso present our most significant foreign currency exposure risk. Changes in foreign currency exchange rates, especially the strengthening of the U.S. dollar, may have an adverse effect on our financial position and results of operations as they are expressed in U.S. dollars.

Our manufacturing and administrative operations for Latin America are located in Argentina. During 2001, severe economic conditions, which have lasted

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

for several years, resulted in a year-end devaluation of the Argentine Peso. As a result, our subsidiary, which has an Argentine Peso functional currency, reported lower U.S. dollar net assets due to the translation impact resulting from the devaluation. Due to the fact that a significant part of our Latin American revenues were denominated in U.S. dollars, our statement of operations reflected a \$1.8 million foreign currency gain from the remeasurement of related accounts receivable as of March 31, 2002.

Management monitors foreign currency exposures and may in the ordinary course of business enter into foreign currency forward contracts or options contracts related to specific foreign currency transactions or anticipated cash flows. These contracts generally cover periods of nine months or less and are not material. We do not hedge the translation of financial statements of consolidated subsidiaries that maintain their local books and records in foreign currencies.

18

### RISK FACTORS

If any of the following risks actually occur, they could harm our business, financial condition, and/or results of operations.

IF WE FAIL TO DEVELOP PRODUCTS FOR THE HEALTH CARE AND AGRI-PROCESSING MARKETS, THEN WE MAY NEVER ACHIEVE A RETURN ON OUR RESEARCH AND DEVELOPMENT EXPENDITURES OR REALIZE PRODUCT REVENUES FROM THESE MARKETS.

A key element of our business strategy is to utilize our technologies for the development and delivery of products to the health care market and new segments of the agri-processing market. We intend to significantly increase our investment in research and development to develop products for these markets. The successful development of products is highly uncertain and is dependent on numerous factors, many of which are beyond our control, and may include the following:

- The product may be ineffective or have undesirable side effects in preliminary and commercial testing or, specifically in the health care area, in preclinical and clinical trials;
- The product may fail to receive necessary governmental and regulatory approvals, or the government may delay regulatory approvals significantly;
- The product may not be economically viable because of manufacturing costs or other factors;
- The product may not gain acceptance in the marketplace; or
- The proprietary rights of others or competing products or technologies for the same application may preclude us from commercializing the product.

Due to these factors we may never achieve a return on our research and development expenditures or realize product revenues from the health care and new agri-processing markets that we are targeting.

IF WE FAIL TO ENTER INTO STRATEGIC ALLIANCES WITH PARTNERS IN OUR TARGET MARKETS

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

OR INDEPENDENTLY RAISE ADDITIONAL CAPITAL, WE WILL NOT HAVE THE RESOURCES NECESSARY TO CAPITALIZE ON ALL OF THE MARKET OPPORTUNITIES AVAILABLE TO US.

We do not currently possess the resources necessary to independently develop and commercialize products for all of the market opportunities that may result from our technologies. We intend to form strategic alliances with industry leaders in our target markets to gain access to funding for research and development, expertise in areas we lack and distribution channels. We may fail to enter into the necessary strategic alliances or fail to commercialize the products anticipated from the alliances. Our alliances could be harmed if:

- We fail to meet our agreed upon research and development objectives;
- We disagree with our strategic partners over material terms of the alliances, such as intellectual property or manufacturing rights; or
- Our strategic partners become competitors or enter into agreements with our competitors.

New strategic alliances that we enter into, if any, may conflict with the business objectives of our current strategic partners and negatively impact existing relationships. In addition, to capitalize on the market opportunities we have identified, we may need to seek additional capital, either through private or public offerings of debt or equity securities. Due to market and other conditions beyond our control, we may not be able to raise additional capital on acceptable terms or conditions, if at all.

19

IF THE DEMAND FOR PROTEIN DEGRADING ENZYMES DECREASES OR IF MAJOR CUSTOMERS REDUCE OR TERMINATE BUSINESS WITH US, OUR REVENUES COULD SIGNIFICANTLY DECLINE.

Our largest selling family of products, protein degrading enzymes, or proteases, accounted for approximately 57% of our 2001 revenues. If the demand for proteases decreases or alternative proteases render our products noncompetitive, our revenues could significantly decline.

In addition, our five largest customers collectively accounted for over 57% of our 2001 product revenues with our largest customer, The Procter & Gamble Company, accounting for over 35% of such revenues. Our five largest customers in 2001 were Benckiser N.V., Cargill, Incorporated, the FinnFeeds Division of Danisco A/ S, The Procter & Gamble Company, and Unilever N.V. Any one of these customers may reduce their level of business with us. Should any of our largest customers decide to reduce or terminate business with us, our revenues and profitability could decline significantly.

We have arrangements of various durations with our major customers and are routinely involved in discussions regarding the status of these relationships. These discussions may lead to extensions or new commercial arrangements, or may be unsuccessful. Our customer relationships involve uncertainty by virtue of economic conditions, customer needs, competitive pressures, our production capabilities and other factors. Consequently, our customer base will change over time as will the nature of our relationships with individual customers, including major customers.

WE INTEND TO ACQUIRE BUSINESSES, TECHNOLOGIES AND PRODUCTS, BUT WE MAY FAIL TO REALIZE THE ANTICIPATED BENEFITS OF SUCH ACQUISITIONS AND WE MAY INCUR COSTS THAT COULD SIGNIFICANTLY NEGATIVELY IMPACT OUR PROFITABILITY.

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

In the future, we may acquire other businesses, technologies and products that we believe are a strategic fit with our business. If we undertake any transaction of this sort, we may not be able to successfully integrate any businesses, products, technologies or personnel that we might acquire without a significant expenditure of operating, financial and management resources, if at all. Further, we may fail to realize the anticipated benefits of any acquisition including our recent acquisition of Enzyme Bio-Systems Ltd. Future acquisitions could dilute our stockholders' interest in us and could cause us to incur substantial debt, expose us to contingent liabilities and could negatively impact our profitability.

IF WE FAIL TO SECURE ADEQUATE INTELLECTUAL PROPERTY PROTECTION OR BECOME INVOLVED IN AN INTELLECTUAL PROPERTY DISPUTE, IT COULD SIGNIFICANTLY HARM OUR FINANCIAL RESULTS AND ABILITY TO COMPETE.

The patent positions of biotechnology companies, including our patent positions, can be highly uncertain and involve complex legal and factual questions and, therefore, enforceability is uncertain. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that we protect our technologies with valid and enforceable patents or as trade secrets. We rely in part on trade secret protection for our confidential and proprietary information by entering into confidentiality agreements and non-disclosure policies with our employees and consultants. Nonetheless, confidential and proprietary information may be disclosed, and others may independently develop substantially equivalent information and techniques or otherwise gain access to our trade secrets.

We file patent applications in the United States and in foreign countries as part of our strategy to protect our proprietary products and technologies. The loss of significant patents or the failure of patents to issue from pending patent applications that we consider significant could impair our operations. In addition, third parties could successfully challenge, invalidate or circumvent our issued patents or patents licensed to us so that our patent rights would not create an effective competitive barrier. Further, we may not obtain the patents or licenses to technologies that we will need to develop products for our target markets. The laws of some foreign countries may also not protect our intellectual property rights to the same extent as United States law.

Extensive litigation regarding patents and other intellectual property rights is common in the biotechnology industry. In the ordinary course of business, we periodically receive notices of potential infringement of patents held by others and patent applications that may mature to patents held by others. The impact of such claims of potential infringement, as may from time to time become known to the Company, are difficult to assess. In the event of an intellectual property dispute, we may become involved in litigation. Intellectual property litigation can be expensive and may divert management's time and resources away from our operations. The outcome of any such litigation is inherently uncertain. Even if we are successful, the litigation can be costly in terms of dollars spent and the diversion of management time.

20

If a third party successfully claims an intellectual property right to technology we use, it may force us to discontinue an important product or product line, alter our products and processes, pay license fees, pay damages for past infringement or cease certain activities. Under these circumstances, we may attempt to obtain a license to this intellectual property; however, we may not be able to do so on commercially reasonable terms, or at all. In addition, regardless of the validity of such a claim, its mere existence may affect the willingness of one or more customers to use or continue to use our products and, thereby, materially impact us.

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

Those companies with which we have entered or may enter into strategic alliances encounter similar risks and uncertainties with respect to their intellectual property. To the extent that any such alliance companies suffer a loss or impairment of their respective technologies, we may suffer a corresponding loss or impairment that may materially and adversely affect our investments.

IF WE FAIL TO ATTRACT AND RETAIN QUALIFIED PERSONNEL, WE MAY NOT BE ABLE TO ACHIEVE OUR STATED CORPORATE OBJECTIVES.

Our ability to manage our anticipated growth, if realized, effectively depends on our ability to attract and retain highly qualified executive officers and technology and business personnel. In particular, our product development programs depend on our ability to attract and retain highly skilled researchers. Competition for such individuals is intense. If we fail to attract and retain qualified individuals, we will not be able to achieve our stated corporate objectives.

FOREIGN CURRENCY FLUCTUATIONS AND ECONOMIC AND POLITICAL CONDITIONS IN FOREIGN COUNTRIES COULD CAUSE OUR REVENUES AND PROFITS TO DECLINE.

In 2001, we derived approximately 50% of our revenues from our foreign operations. Our foreign operations generate sales and incur expenses in local currency. As a result, we are exposed to a market risk related to unpredictable interest rates and foreign currency exchange rate fluctuations. We recognize foreign currency gains or losses arising from our operations in the period incurred. As a result, currency fluctuations between the U.S. dollar and the currencies in which we do business could cause our revenues and profits to decline.

Product revenues denominated in Euros accounted for approximately 21% of total product revenues for 2001, and the fluctuations in the currency exchange rate against the U.S. dollar can have a significant impact on our reported product revenues.

We expect to continue to operate in foreign countries and that our international sales will continue to account for a significant percentage of our revenues. As such, we are subject to certain risks arising from our international business operations that could be costly in terms of dollars spent, the diversion of management's time, and revenues and profits, including:

- Difficulties and costs associated with staffing and managing foreign operations;
- Unexpected changes in regulatory requirements;
- Difficulties of compliance with a wide variety of foreign laws and regulations;
- Changes in our international distribution network and direct sales forces;
- Political trade restrictions and exchange controls;
- Political, social, or economic unrest;
- Labor disputes including work stoppages, strikes and embargoes;
- Inadequate and unreliable services and infrastructure;



## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

- Import or export licensing or permit requirements; and
- Greater risk on credit terms and long accounts receivable collection cycles in some foreign countries.

21

WE EXPECT THAT OUR QUARTERLY RESULTS OF OPERATIONS WILL FLUCTUATE, AND THIS FLUCTUATION COULD CAUSE OUR STOCK PRICE TO DECLINE, CAUSING INVESTOR LOSSES.

A large portion of our expenses, including expenses for facilities, equipment and personnel, are relatively fixed. Accordingly, if product revenue declines or does not grow as we anticipate or non-product revenue declines due to the expiration or termination of strategic alliance agreements or the failure to obtain new agreements or grants, we may not be able to correspondingly reduce our operating expenses in any particular quarter. Our quarterly revenue and operating results have fluctuated in the past and are likely to do so in the future. If our operating results in some quarters fail to meet the expectations of stock market analysts and investors, our stock price would likely decline. Some of the factors that could cause our revenue and operating results to fluctuate include:

- The ability and willingness of strategic partners to commercialize products derived from our technology or containing our products on expected timelines;
- Our ability to successfully commercialize products developed independently and the rate of adoption of such products;
- Fluctuations in consumer demand for products containing our technologies or products, such as back to school sales of blue jeans and other denim products, resulting in an increase in textile processing enzymes, and fluctuations in laundry detergent use due to promotional campaigns run by consumer products companies; and
- Fluctuations in geographic conditions including currency and other economic conditions such as economic crises in Latin America or Asia.

We also have incurred significant one-time charges within given quarters, such as those incurred in conjunction with restructuring activities and recognized investment income from sales of available-for-sale marketable securities.

IF WE ARE SUBJECT TO A COSTLY PRODUCT LIABILITY DAMAGE CLAIM OR AWARD, OUR PROFITS COULD DECLINE.

We may be held liable if any product we develop, or any product that a third party makes with the use or incorporation of any of our products, causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Our current product liability insurance may not cover our potential liabilities. Inability to obtain sufficient insurance coverage in the future at an acceptable cost or otherwise to protect against potential liability claims could prevent or inhibit the commercialization of products developed by us or our strategic partners. If a third party sues us for any injury caused by our products, our liability could exceed our insurance coverage amounts and total assets and our profits could decline.

IF WE ARE SUBJECT TO COSTLY ENVIRONMENTAL LIABILITY DUE TO THE USE OF HAZARDOUS

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

MATERIALS IN OUR BUSINESS, OUR PROFITS COULD DECLINE.

Our research and development processes involve the controlled use of hazardous materials, including chemical, radioactive and biological materials. Our operations also generate hazardous waste. We cannot eliminate entirely the risk of contamination or the discharge of hazardous materials and any resultant injury from these materials. Federal, state, local and foreign laws and regulations govern the use, manufacture, storage, handling and disposal of these materials. Third parties may sue us for any injury or contamination that results from our use or the third party's use of these materials. Any accident could partially or completely shut down our research and manufacturing facilities and operations. In addition, if we are required to comply with any additional applicable environmental laws and regulations, we may incur additional costs, and any such current or future environmental regulations may impair our research, development or production efforts.

### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The information presented in Item 2 of Part I of this Report on Form 10-Q under the heading "Market Risk" is hereby incorporated by reference.

22

## PART II. OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

As of the date of this Report, we are not engaged in any legal proceeding that we expect to have a material adverse effect on our financial condition.

At the time we acquired Enzyme Bio-Systems Ltd. (EBS) in February 2002, EBS was a defendant in a patent infringement claim filed by Novozymes A/S on or about December 4, 2001 in U.S. District Court for the State of Delaware (Civil Action No. 01-804). Genencor International, Inc. is not a party in this action. The former owner of EBS prosecuted a defense with respect to this preexisting claim. This matter has been settled, and the settlement had no material impact on us.

### ITEM 2. CHANGE IN SECURITIES AND USE OF PROCEEDS

During the third quarter of 2000, the Company completed an initial public offering of 8,050,000 shares of common stock at \$18.00 per share. The Company's Registration Statement on Form S-1 (Registration No. 333-36452) was effective as of July 27, 2000 and included 7,000,000 shares of common stock issued July 28, 2001 in the initial offering and 1,050,000 shares of common stock issued August 25, 2000 pursuant to the underwriters' exercise of the over-allotment option. The combined net proceeds from the initial offering and the over-allotment option exercise were approximately \$132.7 million. The Company has used and expects to continue using the net proceeds from the offering for research and development activities, capital expenditures, financing possible acquisitions, working capital and other general corporate purposes.

### ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

- A. EXHIBITS  
See Index to Exhibits
- B. REPORTS ON FORM 8-K  
None

23

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

GENENCOR INTERNATIONAL, INC.

May 15, 2002

-----  
Date

By: /s/ Raymond J. Land

-----  
Raymond J. Land  
Senior Vice President and Chief Financial  
Officer

May 15, 2002

-----  
Date

By: /s/ Darryl L. Canfield

-----  
Darryl L. Canfield  
Vice President and Corporate Controller  
(Chief Accounting Officer)

24

## Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

### INDEX TO EXHIBITS

- (2) PLAN OF ACQUISITION, REORGANIZATION, ARRANGEMENT, LIQUIDATION OR SUCCESSION
- Not applicable.
- (3) ARTICLES OF INCORPORATION AND BY-LAWS
- 3.1 Form of Restated Certificate of Incorporation is incorporated herein by reference to Exhibit 3.3 to Amendment No. 3 to the Company's Registration Statement on Form S-1 (Registration No. 333-36452) filed on July 24, 2000.
- 3.2 Form of Amended and Restated Bylaws is incorporated herein by reference to Exhibit 3.4 to Amendment No. 3 to the Company's Registration Statement on Form S-1 (Registration No. 333-36452) filed on July 24, 2000.
- (4) INSTRUMENTS DEFINING THE RIGHTS OF SECURITIES HOLDERS, INCLUDING INDENTURES
- 4.1 Exhibit 3.1 to this Report is incorporated herein by reference.
- 4.2 Exhibit 3.2 to this Report is incorporated herein by reference.
- 4.3 Form of Specimen Common Stock Certificate is incorporated herein by reference to Exhibit 4.1 to Amendment No. 3 to the Company's Registration Statement on Form S-1 (Registration No. 333-36452) filed on July 24, 2000.
- 4.4 Note Agreement for the \$140,000,000 6.82% Senior Notes due 2006 between the Company and the purchasers identified therein, dated March 28, 1996 is incorporated herein by reference to Exhibit 4.2 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (Registration No. 333-36452) filed on June 26, 2000.
- 4.5 \$32,000,000 Three Year Credit Agreement dated as of January 31, 2001 among the Company, the Lenders party thereto and The Chase Manhattan Bank, as Administrative Agent is incorporated herein by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-8 (Registration No. 333-61450) filed on May 23, 2001.
- 4.6 \$16,000,000 364-Day Credit Agreement dated as of January 31, 2001 among the Company, the Lenders party thereto and The Chase Manhattan Bank, as Administrative Agent is incorporated herein by reference to Exhibit 4.2 to the Company's Registration Statement on Form S-8 (Registration No. 333-61450) filed on May 23, 2001.
- 4.7 Amendment No. 1 dated as of April 20, 2001 to the \$32,000,000 Three Year Credit Agreement dated as of January 31, 2001 among the Company, the Lenders party thereto and The Chase Manhattan Bank, as Administrative Agent is incorporated herein by reference to Exhibit 4.3 to the Company's Registration Statement on Form S-8 (Registration No. 333-61450) filed on May 23, 2001.
- 4.8 Amendment No. 1 dated as of April 20, 2001 to the \$16,000,000 364-Day Credit Agreement dated as of January 31, 2001 among the Company, the Lenders party thereto and The Chase Manhattan Bank, as Administrative Agent is incorporated herein by

Edgar Filing: GENENCOR INTERNATIONAL INC - Form 10-Q

- reference to Exhibit 4.4 to the Company's Registration Statement on Form S-8 (Registration No. 333-61450) filed on May 23, 2001.
- 4.9 Amendment No. 2 dated as of January 31, 2002 to the \$16,000,000 364-Day Credit Agreement dated as of January 31, 2001 among the Company, the Lenders party thereto and The Chase Manhattan Bank, as Administrative Agent is incorporated herein by reference to Exhibit 4.9 to the Company's Annual Report on Form 10-K for the year ended December 31, 2001.
- 4.10 Letter Agreement dated as of January 31, 2002 among JP Morgan Chase Bank, ABN AMRO Bank, NV, the Bank of New York, Credit Suisse First Boston and the Company regarding Credit Agreements dated as of January 31, 2001 and Acquisition of Enzyme Bio-Systems is incorporated herein by reference to Exhibit 4.10 to the Company's Annual Report on Form 10-K for the year ended December 31, 2001.

(10) MATERIAL CONTRACTS

- \*+10.1 Enzyme Supply Agreement between the Company and Corn Products International, Inc., dated February 5, 2002.

(11) STATEMENT RE COMPUTATION OF PER SHARE EARNINGS

Not included as a separate exhibit as computation can be determined from Note 3 to the financial statements included in this Report under Item 1.

25

- (15) LETTER RE UNAUDITED INTERIM FINANCIAL INFORMATION  
Not applicable.
- (18) LETTER RE CHANGE IN ACCOUNTING PRINCIPLES  
Not applicable.
- (19) REPORT FURNISHED TO SECURITY HOLDERS  
Not applicable.
- (22) PUBLISHED REPORT REGARDING MATTERS SUBMITTED TO A VOTE OF SECURITY HOLDERS  
Not applicable.
- (23) CONSENTS OF EXPERTS AND COUNSEL  
Not applicable.
- (24) POWER OF ATTORNEY  
Not applicable.
- (99) ADDITIONAL EXHIBITS  
Not applicable.

- 
- \* Exhibits filed with this Report.
- + Confidential Treatment requested as to certain information which has been separately filed with the Securities and Exchange Commission pursuant to an application for such treatment.

26

